Physician profile
John E Williams
NPI 1619959293
$11,902.14
in general payments reported to CMS, 2019-2025
50 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,477 · 2020: $1,596 · 2021: $3,168 · 2022: $2,142 · 2023: $2,437 · 2024: $82.18.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,519.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,519.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,844.88 | 2019-2023 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $1,270.43 | 2019-2023 | Farxiga |
| Abbvie INC. | $1,127.97 | 2020-2024 | Qulipta, Ubrelvy, Vraylar |
| Amgen INC. | $786.06 | 2019-2023 | Repatha, Otezla, Prolia |
| Pfizer INC. | $667.32 | 2019-2023 | |
| Glaxosmithkline, LLC. | $622.04 | 2019-2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $578.27 | 2019-2023 | Jardiance, Synjardy |
| Lilly USA, LLC | $475.10 | 2019-2023 | Mounjaro |
| Janssen Pharmaceuticals, INC | $411.06 | 2019-2023 | Spravato |
| Astellas Pharma US INC | $364.59 | 2019-2023 | Myrbetriq |
| Abbott Laboratories | $348.09 | 2019-2023 | Freestyle Libre 3, Proclaim |
| Biohaven Pharmaceuticals, INC. | $276.86 | 2020-2021 | |
| Amarin Pharma, INC. | $226.02 | 2019-2022 | |
| Allergan, INC. | $221.97 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $216.49 | 2019-2022 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.